Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18558859 | UNIVERSAL RETARGETING OF ONCOLYTIC HSV | Non-Final OA | Janssen Biotech, Inc. |
| 17913540 | Compositions and Methods for Treatment | Non-Final OA | The Regents of the University of California |
| 18367392 | NEURONAL CELL CULTURES AS COMPUTE SUBSTRATES | Non-Final OA | MICROSOFT TECHNOLOGY LICENSING, LLC |
| 17799239 | BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF | Final Rejection | Juno Therapeutics, Inc. |
| 17580219 | INCREASING GENOME STABILITY AND REPROGRAMMING EFFICIENCY OF INDUCED PLURIPOTENT STEM CELLS | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18248193 | PRODUCTION OF MEGAKARYOCYTES AND PLATELETS IN A CO-CULTURE SYSTEM | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17911018 | COMPOSITION FOR INDUCING APOPTOSIS OF CELLS HAVING GENOMIC SEQUENCE VARIATION AND METHOD FOR INDUCING APOPTOSIS OF CELLS BY USING COMPOSITION | Final Rejection | UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) |
| 18517402 | METHOD FOR PREPARING BROWN ADIPOCYTE | Non-Final OA | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18170671 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED NATURAL KILLER CELLS AND ANTIGEN-SPECIFIC T CELLS, MANUFACTURING METHOD THEREOF, AND METHOD OF USING THE SAME | Final Rejection | NATIONAL YANG MING CHIAO TUNG UNIVERSITY |
| 17620047 | ROTAVIRUS MRNA VACCINE | Final Rejection | CureVac AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy